Mimicking Metastases Including Tumor Stroma: A New Technique to Generate a Three-Dimensional Colorectal Cancer Model Based on a Biological Decellularized Intestinal Scaffold

Tissue Engineering - Part C: Methods

Volumn 22, Issue 7, 2016, Pages 621-635

  Nietzer, Sarah ^a   Baur, Florentin ^a   Sieber, Stefan ^a   Hansmann, Jan ^a   Schwarz, Thomas ^a   Stoffer, Carolin ^a   Häfner, Heide ^b   Gasser, Martin ^a   Waaga Gasser, Ana Maria ^a   Walles, Heike ^a,b   Dandekar, Gudrun ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DISEASES; FIBROBLASTS; GLYCOPROTEINS; PATHOLOGY; SELF ASSEMBLY; TISSUE; TUMORS;

5-FLUOROURACIL (5-FU); BIOLOGICAL SCAFFOLDS; E-CADHERIN EXPRESSION; MESENCHYMAL TO EPITHELIAL TRANSITIONS; MORPHOLOGICAL CHARACTERISTIC; SMALL INTESTINE SUBMUCOSA; THREEDIMENSIONAL (3-D); TUMOR-STROMA INTERACTIONS;

CELLS;

BETA CATENIN; FLUOROURACIL; UVOMORULIN; VIMENTIN;

ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BIOREACTOR; CANCER MODEL; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; COCULTURE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; JEJUNUM; MONOCULTURE; NONHUMAN; PIG; PRIORITY JOURNAL; PROTEIN EXPRESSION; THREE DIMENSIONAL COLON CANCER MODEL; TISSUE ENGINEERING; TISSUE SCAFFOLD; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BIOLOGICAL MODEL; CACO-2 CELL LINE; CELL CULTURE TECHNIQUE; COLORECTAL TUMOR; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PROCEDURES; SECONDARY; SKIN; STROMA CELL; TUMOR MICROENVIRONMENT;

ANIMALS; CACO-2 CELLS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; COCULTURE TECHNIQUES; COLORECTAL NEOPLASMS; FIBROBLASTS; HUMANS; INTESTINAL MUCOSA; MODELS, BIOLOGICAL; SKIN; STROMAL CELLS; SWINE; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TUMOR MICROENVIRONMENT;

EID: 84978394027     PISSN: 19373384     EISSN: 19373392     Source Type: Journal    
DOI: 10.1089/ten.tec.2015.0557     Document Type: Article

References (48)

1. Bhattacharjee, Y. Biomedicine. Pharma firms push for sharing of cancer trial data. Science 338, 29, 2012.
2. Bissell, M.J., and Radisky, D. Putting tumours in context. Nat Rev Cancer 1, 46, 2001.
3. Hanahan, D., and Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646, 2011.
4. Debnath, J., and Brugge, J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5, 675, 2005.
5. Fischbach, C., Chen, R., Matsumoto, T., Schmelzle, T., Brugge, J.S., Polverini, P.J., and Mooney, D.J. Engineering tumors with 3D scaffolds. Nat Methods 4, 855, 2007.
6. Kalluri, R., and Zeisberg, M. Fibroblasts in cancer. Nat Rev Cancer 6, 392, 2006.
7. Banyard, J., and Bielenberg, D.R. The role of EMT and MET in cancer dissemination. Connect Tissue Res 56, 403, 2015.
8. Friedl, P., Locker, J., Sahai, E., and Segall, J.E. Classifying collective cancer cell invasion. Nat Cell Biol 14, 777, 2012.
9. Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J.F., Harrington, K., and Sahai, E. Fibroblast-led collective invasion of carcinoma cells with differing roles for Rho GTPases in leading and following cells. Nat Cell Biol 9, 1392, 2007.
10. Yao, D., Dai, C., and Peng, S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 9, 1608, 2011.
11. Hoppensack, A., Kazanecki, C.C., Colter, D., Gosiewska, A., Schanz, J., Walles, H., and Schenke-Layland, K. A human in vitro model that mimics the renal proximal tubule. Tissue Eng Part C Methods 20, 599, 2014.
12. Stratmann, A.T., Fecher, D., Wangorsch, G., Gottlich, C., Walles, T., Walles, H., Dandekar, T., Dandekar, G., and Nietzer, S.L. Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. Mol Oncol 8, 351, 2014.
13. Linke, K., Schanz, J., Hansmann, J., Walles, T., Brunner, H., and Mertsching, H. Engineered liver-like tissue on a capillarized matrix for applied research. Tissue Eng 13, 2699, 2007.
14. Schanz, J., Pusch, J., Hansmann, J., and Walles, H. Vascularised human tissue models: a new approach for the refinement of biomedical research. J Biotechnol 148, 56, 2010.
15. Jannasch, M., Groeber, F., Brattig, N.W., Unger, C., Walles, H., and Hansmann, J. Development and application of three-dimensional skin equivalents for the investigation of percutaneous worm invasion. Exp Parasitol 150, 22, 2015.
16. Moll, C., Reboredo, J., Schwarz, T., Appelt, A., Schurlein, S., Walles, H., and Nietzer, S. Tissue engineering of a human 3D in vitro tumor test system. J Vis Exp 78, 50460, 2013.
17. Biazik, J.M., Jahn, K.A., Su, Y., Wu, Y.N., and Braet, F. Unlocking the ultrastructure of colorectal cancer cells in vitro using selective staining. World J Gastroenterol 16, 2743, 2010.
18. Petrowsky, H., Sturm, I., Graubitz, O., Kooby, D.A., Staib-Sebler, E., Gog, C., Kohne, C.H., Hillebrand, T., Daniel, P.T., Fong, Y., and Lorenz, M. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 27, 80, 2001.
19. Cree, I.A., Glaysher, S., and Harvey, A.L. Efficacy of anticancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10, 375, 2010.
20. Kammerer, R., Ehret, R., and von Kleist, S. Isolated extracellular matrix-based three-dimensional in vitro models to study orthotopically cancer cell infiltration and invasion. Eur J Cancer 34, 1950, 1998.
21. Mertsching, H., Schanz, J., Steger, V., Schandar, M., Schenk, M., Hansmann, J., Dally, I., Friedel, G., and Walles, T. Generation and transplantation of an autologous vascularized bioartificial human tissue. Transplantation 88, 203, 2009.
22. Steinke, M., Dally, I., Friedel, G., Walles, H., and Walles, T. Host-integration of a tissue-engineered airway patch: two-year follow-up in a single patient. Tissue Eng Part A 21, 573, 2015.
23. Heinlein, A., Metzger, M., Walles, H., and Buettner, A. Transport of hop aroma compounds across Caco-2 monolayers. Food Funct 5, 2719, 2014.
24. Giusti, S., Sbrana, T., La Marca, M., Di Patria, V., Martinucci, V., Tirella, A., Domenici, C., and Ahluwalia, A. A novel dual-flow bioreactor simulates increased fluorescein permeability in epithelial tissue barriers. Biotechnol J 9, 1175, 2014.
25. Pusch, J., Votteler, M., Gohler, S., Engl, J., Hampel, M., Walles, H., and Schenke-Layland, K. The physiological performance of a three-dimensional model that mimics the microenvironment of the small intestine. Biomaterials 32, 7469, 2011.
26. Ostman, A., and Augsten, M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 19, 67, 2009.
27. Liotta, L.A., and Kohn, E.C. The microenvironment of the tumour-host interface. Nature 411, 375, 2001.
28. Fleming, M., Ravula, S., Tatishchev, S.F., and Wang, H.L. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol 3, 153, 2012.
29. Peddareddigari, V.G., Wang, D., and Dubois, R.N. The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron 3, 149, 2010.
30. Lee, J.M., Dedhar, S., Kalluri, R., and Thompson, E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172, 973, 2006.
31. Chen, Z., He, X., Jia, M., Liu, Y., Qu, D., Wu, D., Wu, P., Ni, C., Zhang, Z., Ye, J., Xu, J., and Huang, J. b-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis. PLoS One 8, e63854, 2013.
32. Wong, N.A., and Pignatelli, M. Beta-catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 160, 389, 2002.
33. Wells, A., Yates, C., and Shepard, C.R. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 25, 621, 2008.
34. Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A., Knuechel, R., and Kirchner, T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 98, 10356, 2001.
35. Orimo, A., Gupta, P.B., Sgroi, D.C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V.J., Richardson, A.L., and Weinberg, R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335, 2005.
36. Radisky, D.C., Levy, D.D., Littlepage, L.E., Liu, H., Nelson, C.M., Fata, J.E., Leake, D., Godden, E.L., Albertson, D.G., Nieto, M.A., Werb, Z., and Bissell, M.J. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436, 123, 2005.
37. Friedl, P., and Wolf, K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 68, 7247, 2008.
38. Herdrich, K., and Weinberger, H. Selected Schedules of Therapy for Malignant Tumors. Frankfurt am Main, Germany: Baxter Oncology, 2003.
39. Bracht, K., Nicholls, A.M., Liu, Y., and Bodmer, W.F. 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br J Cancer 103, 340, 2010.
40. Yoshikawa, R., Kusunoki, M., Yanagi, H., Noda, M., Furuyama, J.I., Yamamura, T., and Hashimoto-Tamaoki, T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61, 1029, 2001.
41. Mhaidat, N.M., Bouklihacene, M., and Thorne, R.F. 5-Fluorouracil-induced apoptosis in colorectal cancer cells is caspase-9-dependent and mediated by activation of protein kinase C-delta. Oncol Lett 8, 699, 2014.
42. Bocci, G., Danesi, R., Di Paolo, A.D., Innocenti, F., Allegrini, G., Falcone, A., Melosi, A., Battistoni, M., Barsanti, G., Conte, P.F., and Del Tacca, M. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 6, 3032, 2000.
43. de Vos tot Nederveen Cappel, W.H., Meulenbeld, H.J., Kleibeuker, J.H., Nagengast, F.M., Menko, F.H., Griffioen, G., Cats, A., Morreau, H., Gelderblom, H., and Vasen, H.F. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 109, 468, 2004.
44. Loehrer, P.J., Sr., Turner, S., Kubilis, P., Hui, S., Correa, J., Ansari, R., Stephens, D., Woodburn, R., and Meyer, S. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment ofmetastatic colorectal cancer: a Hoosier Oncology Group trial. J Clin Oncol 6, 642, 1988.
45. Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., and Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041, 2000.
46. Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J.F., Letourneau, Y., Coudert, B., Bertheaut-Cvitkovic, F., Larregain-Fournier, D., Le Rol, A., Walter, S., Adam, R., Misset, J.L., and Levi, F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18, 136, 2000.
47. Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., Nakamura, Y., White, R., Smits, A.M., and Bos, J.L. Genetic alterations during colorectal-tumor development. N Engl JMed 319, 525, 1988.
48. Lievre, A., Bachet, J.B., Le Corre, D., Boige, V., Landi, B., Emile, J.F., Cote, J.F., Tomasic, G., Penna, C., Ducreux, M., Rougier, P., Penault-Llorca, F., and Laurent-Puig, P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66, 3992, 2006.